Sanofi ADR share price logo

Sanofi ADR

NASDAQ: SNY

Large Cap

$45.92

-0.86

(-1.84%)

as on

Sanofi ADR Stock Performance

as on April 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $45.87
    $46.85
    downward going graph

    0.11%

    Downside

    2.03%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $43.32
    $55.73
    downward going graph

    5.66%

    Downside

    21.36%

    Upside

    downward going graph

Sanofi ADR share price movements today

Previous Close
$46.78
Open
$46.38
Volume
2.7M
Day's Low - High
$45.87 - $46.85
52 Week Low - High
$43.32 - $55.73

Sanofi ADR Historical Returns

1 Month Return
0 %
3 Month Return
-1.5 %
1 Year Return
-10.59 %
3 Year Return
-16.6 %
5 Year Return
-9.27 %

Sanofi ADR Stock Fundamentals & Key Indicators

Check Sanofi ADR market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$112.1B

EPS (TTM)

4.9569

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.02%

PE Ratio (TTM)

20.16

Industry PE ratio

20.459

PEG Ratio

4.4413

EBITDA

12.6B

Revenue (TTM)

46.7B

Profit Margin

16.72%

Return On Equity TTM

6.66%

Sanofi ADR Stock Valuation

Track how Sanofi ADR P/E has moved over time to understand its valuation trends.

Sanofi ADR in the last 5 years

  • Overview

  • Trends

Lowest (8.47x)

December 31, 2023

Today (20.16x)

April 27, 2026

Industry (20.46x)

April 27, 2026

Highest (14.50x)

June 30, 2021

LowHigh

Today’s Price to Earnings Ratio: 20.16x

Sanofi ADR vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Sanofi ADR with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$112.1B-9.27%20.1616.72%
BUY$294.2B262.33%28.9717.41%
BUY$789.7B385.13%38.4731.67%
BUY$547.6B39.42%26.3921.83%
BUY$351.5B78.31%84.26.91%

Stock Returns calculator for Sanofi ADR Stock including INR - Dollar returns

The Sanofi ADR stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Sanofi ADR investment value today

Current value as on today

₹97,071

Returns

-₹2,929

(-2.93%)

Returns from Sanofi ADR Stock

-₹12,232 (-12.23%)

Dollar Impact

₹9,304 (+9.3%)

Analyst Recommendation on Sanofi ADR Stock

Based on 31 analysts

BUY

74.19%

Buy

22.58%

Hold

3.23%

Sell

Based on 31 analysts, 74.19% of analysts recommend a 'BUY' rating for Sanofi ADR. Average target price of $56.12

Sanofi ADR Share Price Target

Get share price movements and forecasts by analysts on Sanofi ADR.

What analysts predicted

18.18%UPSIDE

Target Price

$56.12

Current Price

$45.92

Analyzed by

31 Analysts

Target

$56.12

Sanofi ADR target price $56.12, a slight upside of 18.18% compared to current price of $45.92. According to 31 analysts rating.

Sanofi ADR Stock’s Investor Sentiment and Interest

Search interest for Sanofi ADR Stock has increased by 33% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:33% versus previous 30 day period

Sanofi ADR Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
13,309
10,571
12,245
15,720
7,983
11,469
10,735
13,170
12,205
11,244
Gross Profit
8,894
7,344
8,576
11,184
5,607
8,345
7,743
9,758
8,575
8,106
Operating Income
342
1,236
1,595
3,635
573
2,285
1,474
3,623
-1,038
2,269
EBITDA
425
1,867
2,026
4,247
563
2,770
1,889
4,198
3,823
2,716
Interest Expense
293
247
304
265
302
213
201
227
100
178
Depreciation
575
562
499
479
209
399
378
461
538
535
Income Before Tax
-249
1,093
1,416
3,581
451
2,200
1,467
3,508
-1,155
2,014
Income Tax Expense
309
104
299
737
4
481
230
680
-348
420
Net Income
-605
1,231
1,197
3,125
522
2,024
3,940
2,802
-801
1,614
Net Profit Margin
-4.55%
11.65%
9.78%
19.88%
6.54%
17.65%
36.70%
21.28%
-6.56%
14.35%

Sanofi ADR Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
36,572
42,854
40,583
41,816
45,452
44,285
42,923
45,400
46,333
46,716
Gross Profit
25,292
29,114
27,576
28,505
30,663
30,431
30,349
31,624
32,517
33,793
Operating Income
6,531
5,804
4,676
3,051
14,113
8,126
10,162
6,960
7,252
6,344
EBITDA
9,900
9,637
9,179
10,662
17,883
11,538
13,510
11,390
11,033
12,680
Interest Expense
399
333
486
536
430
377
384
512
622
540
Depreciation
-
3,686
4,279
7,452
3,684
1,580
2,053
4,792
3,586
5,678
Income Before Tax
5,811
5,616
4,904
3,007
14,137
7,837
9,992
6,115
6,758
6,020
Income Tax Expense
1,325
1,722
481
121
1,807
1,558
1,909
1,017
1,204
1,043
Net Income
4,963
9,957
4,898
3,060
14,953
7,034
8,858
5,890
5,817
7,813
Net Profit Margin
13.57%
23.24%
12.07%
7.32%
32.90%
15.89%
20.64%
12.98%
12.55%
16.72%

Sanofi ADR Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
1,133
1,113
2,815
683
1,872
3,940
2,802
-801
1,614
Operating Cash Flow
88
1,423
3,848
-
2,093
1,462
3,750
3,445
1,683
Investing Cash Flow
-
-3,413
-
-
-776
-
-9,043
-2,131
-
Financing Cash Flow
760
89
-1,872
-
-592
-3,857
-1,148
-2,570
-1,527
Change in Cash
471
-1,915
-
-
550
7,368
8,906
-1,249
-2,113

Sanofi ADR Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
8,434
4,306
2,754
12,294
6,223
8,371
5,400
5,496
7,813
Operating Cash Flow
7,379
5,547
7,715
7,418
10,522
10,526
10,258
9,081
10,750
Investing Cash Flow
639
-12,872
-1,212
3,588
-7,298
-2,075
-6,200
-4,407
-2,350
Financing Cash Flow
-7,902
3,934
-4,193
-6,485
-7,056
-5,821
-8,052
-5,763
-8,207
Change in Cash
42
-3,390
2,502
4,488
-3,817
2,638
-4,026
-1,269
216

Global Institutional Holdings in Sanofi ADR

Funds
Holdings
Morgan Stanley - Brokerage Accounts
0.32%
Natixis Advisors, LLC.
0.13%
Fisher Asset Management, LLC
0.52%
Barrow Hanley Mewhinney & Strauss LLC
0.29%
Amvescap Plc.
0.24%

Sanofi ADR News & Key Events

  • img

    Today's Timeline - 27 April

    Mon, 10:40 AM

    -

    Sanofi prices €2.3 billion bond issue for general corporate purposes, comprising three tranches.

    Mon, 11:24 AM

    -

    Sanofi reports Q1 2026 results with 13.6% sales growth and €1.88 EPS, driven by strong pharma launches.

Insights on Sanofi ADR

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Sanofi has shown impressive profit growth over the last two quarters. Its net profit has increased from $801 million to $1.61 billion, reflecting an average quarterly increase of 149.6%. This trend indicates strong financial performance for the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, ASTRAZENECA PLC has given 157.2% return, outperforming this stock by 173.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, ASTRAZENECA PLC has given 172.7% return, outperforming this stock by 183.3%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Sanofi has experienced a decline in revenue for the last three quarters. The revenue dropped from $13.17 billion to $11.24 billion, resulting in an average decrease of 7.6% per quarter.

About Sanofi ADR

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
OrganisationSanofi ADR
Headquarters46, avenue de la Grande ArmEe, Paris, France, 75017
IndustryDrug Manufacturers - General
CEOMr. Olivier Charmeil
E-voting on sharesClick here to vote

Key Management of Sanofi ADR

Name

Title

Mr. Erik Wallström

Head of Therapeutic Area - Neurology Development

Mr. Thomas Triomphe

Executive Vice President of Vaccines

Mr. Olivier Charmeil

Interim CEO & Executive VP of General Medicines

Mr. François-Xavier Roger

Executive VP & CFO

Ms. Madeleine Roach

Executive VP & Head of Business Operations

Ms. Natalie Bickford

Executive VP & Chief People Officer

Mr. Thomas Kudsk Larsen

Head of Investor Relations & General Medicines

Mr. Roy Papatheodorou

Executive VP & General Counsel

Mr. Pierre Chancel

Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing

Fabrizio Gaudi

Head of Austrian, German & Swiss Operations

FAQs

What is Sanofi ADR share price today?

Sanofi ADR share price today is $45.92 as on at the close of the market. Sanofi ADR share today touched a day high of $46.85 and a low of $45.87.

What is the 52 week high and 52 week low for Sanofi ADR share?

Sanofi ADR share touched a 52 week high of $55.73 on and a 52 week low of $43.32 on . Sanofi ADR stock price today i.e. is closed at $45.92,which is 17.60% down from its 52 week high and 6.00% up from its 52 week low.

What is Sanofi ADR's market capitalisation today?

Sanofi ADR market capitalisation is $0.11T as on .

How to invest in Sanofi ADR Stock (SNY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Sanofi ADR on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sanofi ADR Shares that will get you 0.0327 shares as per Sanofi ADR share price of $45.92 per share as on April 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Sanofi ADR Stock (SNY) from India?

Indian investors can start investing in Sanofi ADR (SNY) shares with as little as ₹94.19 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹941.90 in Sanofi ADR stock (as per the Rupee-Dollar exchange rate as on ). Based on Sanofi ADR share’s latest price of $45.92 as on April 28, 2026 at 1:29 am IST, you will get 0.2178 shares of Sanofi ADR. Learn more about fractional shares .

What are the returns that Sanofi ADR has given to Indian investors in the last 5 years?

Sanofi ADR stock has given -9.27% share price returns and 26.36% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?